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The proteasome is an essential evolutionary con-
served protease involved in many regulatory systems.
Here, we describe the synthesis and characterization
of the activity-based, fluorescent, and cell-permeable
inhibitor Bodipy TMR-Ahx3L3VS (MV151), which spe-
cifically targets all active subunits of the proteasome
and immunoproteasome in living cells, allowing for
rapid and sensitive in-gel detection. The inhibition
profile of a panel of commonly used proteasome inhib-
itors could be readily determined by MV151 labeling.
Administration of MV151 tomice allowed for in vivo la-
beling of proteasomes, which correlated with inhibi-
tion of proteasomal degradation in the affected tis-
sues. This probe can be used for many applications
ranging from clinical profiling of proteasome activity,
to biochemical analysis of subunit specificity of inhib-
itors, and to cell biological analysis of the proteasome
function and dynamics in living cells.
Introduction
The 26S proteasome is the central protease in ATP- and
ubiquitin-dependent degradation of proteins in the eu-
karyotic cytoplasm and nucleus and is responsible for
the degradation of 80%–90% of all cellular proteins.
The proteasome is involved in the degradation of abnor-
*Correspondence: h.s.overkleeft@chem.leidenuniv.nl
5 These authors contributed equally to this work.mal and damaged proteins, cell-cycle regulators, onco-
gens, and tumor suppressors, and it is imperative in the
generation of MHC class I antigenic peptides [1]. Eu-
karyotic proteasomes contain two copies of seven dis-
tinct a and b subunits each. These subunits assemble
into two types of heterooligomeric rings that are each
composed of seven subunits (a1–a7 and b1–b7). The
20S proteasome is formed by two juxtaposed rings of
b subunits flanked on top and bottom by a ring of a sub-
units [2]. When capped by the 19S regulatory complex at
both ends, the proteolytically active 26S proteasome is
formed and is responsible for ATP-dependent proteoly-
sis of polyubiquitinated target proteins [3].
In the eukaryotic proteasome, three of the seven
b subunits are responsible for the proteolytic activities
of the proteasome. Characterization of the active b1,
b2, and b5 subunits led to the classification of their sub-
strate specificity as peptidylglutamyl peptide hydrolytic,
trypsin-like, and chymotrypsin-like, respectively. In im-
mune-competent cells, three additional activeb subunits
(bi) are expressed upon interferon-g stimulation. These
subunits assemble in a new proteasome particle called
the immunoproteasome, which coexists with the consti-
tutive proteasome [2].
The proteolytic subunits b1, b2, and b5 and their im-
munoproteasomal counterparts, b1i, b2i, and b5i, re-
spectively, act by nucleophilic attack of the g-hydroxyl
of the N-terminal threonine on the carbonyl of the pep-
tide bond destined for cleavage. The a-amine of the
threonine acts as a base in the catalytic cycle. The exis-
tence and evolutionary development of six different ac-
tive b subunits, their divergent substrate specificities,
and their individual roles in cellular processes constitute
a vast research field of interest in both academia and the
pharmaceutical industry. This scientific demand can
benefit from an activity-based proteasome probe that
ideally (1) specifically targets the proteasome, (2) cova-
lently and irreversibly binds to the three active b and bi
subunits indiscriminately, (3) facilitates direct, rapid, ac-
curate, and sensitive detection, (4) is cell permeable,
and (5) enables monitoring of the proteasome by micro-
scopic techniques in living cells.
To date, none of the available activity-based protea-
some probes meet all of these requirements [4, 5]. The
compound that comes closest is the radiolabeled pro-
teasome inhibitor AdaY(125I)Ahx3L3VS [6]. In this com-
pound, the leucine vinyl sulfone mimics the peptide car-
bonyl and acts as a nucleophilic trap that covalently
modifies the g-hydroxyl of the N-terminal threonine
through a Michael addition. This inhibitor is selective
for the proteasome, labels the b subunits with equal
intensity, and enables accurate and sensitive in-gel
detection. However, usage of this activity-based probe
is restricted to in vitro applications since this com-
pound is not cell permeable. Recently, the weakly fluo-
rescent and cell-permeable proteasome inhibitor dansyl-
Ahx3L3VS was developed for profiling proteasome
activity in living cells, enabling readout by antidansyl
immunoblotting [7]. The low quantum yield and near-
UV excitation of the dansyl makes this compound
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1218Figure 1. The Synthesis of Bodipy TMR-Ahx3L3VS, 6, and the Control Compound Bodipy TMR-Ahx3L3ES, 7
Reagents and conditions: (a) TFA/DCM 1/1 (v/v), 30 min. (b) 2 (2 equiv.), BOP (2.5 equiv.), DiPEA (6 equiv.), 12 hr, 98%. (c) (i) DBU (1 equiv.),
DMF, 5 min; (ii) HOBt (4.5 equiv.), 1 min; (iii) 5 (1 equiv.), DiPEA (6 equiv.), 30 min, 99%. (d) (i) Pd/C, H2, MeOH; (ii) DBU (1 equiv.), DMF, 5 min; (iii)
HOBt (4.5 equiv.), 1 min; (iv) 5 (1 equiv.), DiPEA (6 equiv.), 30 min, 89%.unsatisfactory for in-gel detection and standard fluores-
cence microscopic techniques.
Here, we present the synthesis and characterization
of the fluorescent, cell-permeable, and activity-based
proteasome probe Bodipy TMR-Ahx3L3VS (MV151).
After proteasome labeling and protein separation by
SDS-PAGE, the modified proteasome subunits are im-
mediately visualized by in-gel fluorescence readout.
Furthermore, this compound enables fast and sensitive
labeling of proteasomes in vitro, in cells, and in mice; is
compatible with live-cell imaging techniques; and facili-
tates screening and determination of the subunit speci-
ficity of novel proteasome inhibitors.
Results and Discussion
Synthesis of Bodipy TMR-Ahx3L3VS
Bodipy TMR-Ahx3L3VS (MV151, 6) and the inactive, neg-
ative control, Bodipy TMR-Ahx3L3ES (MV152, 7), in
which the vinyl sulfone moiety is reduced to an ethyl sul-
fone, were synthesized as depicted in Figure 1. Acidic
cleavage of Fmoc-Ahx3-Wang resin (3), synthesized by
using standard Fmoc-based solid-phase peptide chem-
istry, gave the crude Fmoc-Ahx3-OH, which was block
coupled to TFA$H-Leu3VS (2) [8], to yield Fmoc-pro-
tected hexapeptide (4). In situ deprotection of theFmoc-protecting group with DBU and treatment with
Bodipy TMR succinimidyl ester (5) ([9–11, 12]; see
the Supplemental Data available with this article online)
afforded target compound 6. In order to obtain the
inactive control compound 7, hexapeptide 4 was first
treated with hydrogen gas and palladium on charcoal
in methanol to reduce the vinyl sulfone, followed by
Fmoc cleavage and introduction of the Bodipy TMR
moiety.
Proteasome Labeling and In-Gel Detection
The potency of MV151 (6) was determined by measuring
proteasomal activity by using fluorogenic substrates.
EL-4 lysates were incubated with increasing concentra-
tions of MV151, and the cleavage of the substrates
Suc-Leu-Leu-Val-Tyr-AMC (chymotrypsin-like activity),
Z-Ala-Ala-Arg-AMC (trypsin-like activity), and Z-Leu-
Leu-Glu-bNA (peptidylglutamyl peptide hydrolytic activ-
ity) was monitored. At concentrations below 1 mM,
MV151 appears to inhibit trypsin-like activity and chy-
motrypsin-like activity more efficiently than it inhibits
PGPH activity (Figure 2A). This might be due to differ-
ences in activity between the subunits, to allosteric ef-
fects, to minor subunit specificities of the probe, or to
nonsaturation kinetics. At concentrations of 1 mM and
higher, MV151 completely inhibits all three activities.
In Vivo Labeling of the Proteasome
1219Figure 2. Proteasome Labeling and In-Gel Detection from Cell Extracts
(A) Measurement of proteasome activity with fluorogenic substrates after treatment of EL-4 lysates with the indicated concentrations of MV151
(PGPH, peptidylglutamyl peptide hydrolytic activity; TL, trypsin-like activity; CtL, chymotrypsin-like activity).
(B and C) Comparison between fluorescent in-gel detection and silver staining. The indicated amounts of purified human 20S proteasome and
BSA (1 mg) were incubated for 1 hr at 37C with 300 nM MV151, resolved by SDS-PAGE, and detected by (B) direct fluorescence in-gel readout
and by (C) silver staining.
(D and E) Proteasome labeling profile in (D) EL-4 and (E) HeLa lysates (10 mg) incubated for 1 hr at 37C with the indicated concentrations of
MV151. ‘‘M’’ represents the molecular marker (Dual Color, BioRad); ‘‘2’’ represents heat-inactivated lysates incubated with 10 mM MV151 for 1
hr at 37C.Direct in-gel visualization of MV151-labeled protea-
some subunits was explored by using a fluorescence
scanner. Treatment of purified human 20S proteasome
with MV151 showed uniform labeling of the active sub-
units b1, b2, and b5 (Figure 2B). To determine the sensi-
tivity of the in-gel detection, we directly compared fluo-
rescence readout of the gel (Figure 2B) with detection of
proteasome subunits by silver staining of proteins
(Figure 2C). The in-gel detection was shown to be very
sensitive since as little as 3 ng proteasome was suffi-
cient to detect individual MV151-labeled proteasome
subunits; detection with this method is at least three
times more sensitive than silver staining.
We next compared the labeling of the constitutive b1,
b2, and b5 subunits and the immunoproteasome b1i, b2i,
and b5i subunits. For this purpose, we labeled the pro-
teasomes in lysates of the human cervix carcinoma
cell line HeLa (expressing constitutive proteasome)
and the murine lymphoid cell line EL-4 (expressing
both constitutive and immunoproteasome) with increas-
ing concentrations of MV151. All active constitutive and
inducible b proteasome subunits were neatly and uni-
formly labeled by MV151 (Figures 2D and 2E). All sub-
units were already detectable at a concentration of 10
nM MV151 and reached saturation in fluorescence sig-
nal at 1 mM MV151. At higher concentrations of MV151,
an increased nonspecific labeling was observed in the
high molecular weight region.
Proteasome Profiling Screen of Known Inhibitors
Next, we performed competition experiments with
MV151 to determine the subunit specificity of a panelof known proteasome inhibitors. EL-4 and HeLa cell ly-
sates (10 mg total protein) were first incubated for 1 hr
with the inhibitor of interest. After incubation with the
proteasome inhibitor, the subunits that were still active
were fluorescently labeled by treating the lysates with
100 nM MV151 for 1 hr.
In HeLa lysates, epoxomicin preferentially inhibits the
b5 subunit, already visible at a 10 nM concentration. At
epoxomicin concentrations over 100 nM, b1 and b2 are
also targeted, with a slight preference for b2 (at 5 mM ep-
oxomicin, b2 fluorescence is absent and a faint band of
b1 is still visible) (Figure 3A, right panel). This is in accor-
dance with the inhibition profile of epoxomicin deter-
mined with purified 20S proteasome [12]. Interestingly,
in EL-4 lysates, epoxomicin preferentially inactivates
b2 and b2i and is less active toward constitutive and im-
munoinduced b1 and b5 subunits (Figure 3A, left panel).
Dansyl-Ahx3L3VS [7] inhibits all active constitutive and
immunoinduced subunits in EL-4 from concentrations of
500 nM and greater (Figure 3B, left panel). In HeLa ly-
sates, dansyl-Ahx3L3VS has a preference for the b5 sub-
unit, which is visible at 100 nM, and less of a preference
for the b1 and b2 subunits, which are visible at slightly
higher concentrations (Figure 3B, right panel).
The dipeptidyl pinanediol boronic ester (pinanediol
boronic ester of Bortezomib [13]) shows a strong selec-
tivity for the constitutive b1 and b5 subunits in HeLa ly-
sates (Figure 3C, right panel) and b1, b1i, b5, and b5i in
EL-4 lysates (Figure 3C, left panel). The inhibition profile
of the dipeptidyl pinanediol boronic ester is comparable
to the labeling profile of Bortezomib [7], with potency in
the same order of magnitude.
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(A–F) EL-4 and HeLa lysates (10 mg total protein) were incubated with the indicated concentrations of the (A) proteasome inhibitor epoxomicin,
(B) dansyl-Ahx3L3VS, (C) dipeptidyl pinanediol boronic ester, (D) NLVS, (E) ZLVS, and (F) Ada-Ahx3L3VS for 1 hr at 37
C. The remaining activity
of the b subunits was fluorescently labeled by incubation with 0.1 mM MV151 for 1 hr at 37C.As previously reported, NLVS [8] shows a predilection
for b5 (Figure 3D), whereas ZLVS [8] (Figure 3E) proves to
be the least potent compound and shows some prefer-
ence for constitutive and immunoinduced b1 and b5
subunits.
In EL-4 lysates, ada-Ahx3L3VS [6] first targets the b2
and b2i subunits, and it shows a preference for b2 and
b5 in HeLa lysates (Figure 3F).
Altogether, this experiment shows that MV151 can be
used for the determination of inhibition profiles of pro-
teasome inhibitors. Exploiting the sensitivity of in-gel
detection of MV151, it is possible to demonstrate that
the inhibitors tested show subtle differences in the pro-
teasome inhibition profile.
Functional Proteasome Inhibition in Living Cells
We next addressed whether MV151 is able to label
proteasome subunits in living cells. EL-4 and HeLa
cells were incubated with increasing concentrations of
MV151. Specific and sensitive labeling of all proteasome
subunits was observed in EL-4 (Figure 4A) and HeLa
cells (Figure 4B), although higher concentrations were
required than for labeling of subunits in lysates. Labeling
of the b1 subunit shows a lower intensity than in lysates,
whereas b5 labeling looks more pronounced. This differ-
ence in the labeling profile between the proteasome in
cell lysates and living cells has been previously reported
[7]; however, the reason for this remains unclear. Impor-
tantly, incubation of EL-4 and HeLa cells with the inac-
tive control compound MV152 (7), which is almost iden-
tical to MV151 but lacks the reactive vinyl sulfone
warhead, showed no labeling of the proteasome or any
other protein (Figures 4A and 4B).In vivo functionality of MV151 was determined in HeLa
cells stably expressing a green fluorescent protein (GFP)
reporter proteasome substrate [14]. The ubiquitinG76V-
GFP (UbG76V-GFP) fusion expressed by these cells is
normally rapidly degraded by the proteasome. Indeed,
untreated UbG76V-GFP HeLa cells emitted only low
levels of GFP fluorescence (Figure 4C, left panel). Cells
that were exposed to 10 mM of the inactive MV152 for
12 hr did accumulate the control compound, but they
did not show increased levels of GFP fluorescence
(Figure 4C, middle panel). During 12 hr of exposure to
10 mM MV151, cells accumulated the inhibitor and
showed significantly increased levels of GFP fluores-
cence (Figure 4C, right panel). Strong fluorescence is
apparent in the membranous compartments of cells
treated with the inactive MV152. This fluorescence,
which appears to be stronger than in MV151-treated
cells, and which is not due to proteasome labeling (as
judged from SDS-PAGE analysis), is likely due to accu-
mulation of MV152 in the hydrophobic environment of
the membranes. The active MV151 is likely not to accu-
mulate in the lipid bilayers, because it is sequestered by
the proteasome active sites. It should be noted that
Bodipy dyes fluoresce strongly in hydrophobic environ-
ments. There was no visual evidence of cellular toxicity
at the dose and exposure time used in this study. These
results were confirmed by a study with the human mela-
noma cell line MelJuSo stably expressing the N-end-rule
reporter proteasome substrate Ub-R-GFP [14] (data not
shown).
We next set out to determine whether the intracellular
staining pattern of MV151 colocalized with the protea-
some in living cells. To this end, we used MelJuSo cells
In Vivo Labeling of the Proteasome
1221Figure 4. Functional Proteasome Inhibition in Living Cells
(A and B) Proteasome profiling in living (A) EL-4 and (B) HeLa cells after a 2 hr incubation with the indicated concentrations of MV151. As a con-
trol, the cells were incubated with the inactive compound MV152. A purified proteasome labeled with MV151 is also shown.
(C) Representative micrographs of UbG76V-GFP HeLa cells that were untreated (left panel), incubated for 12 hr with 10 mM inactive MV152 (mid-
dle panel), and incubated for 12 hr with 10 mM MV151 (right panel). Bodipy TMR and UbG76V-GFP fluorescence are shown.
(D–F) Colocalization of a GFP-labeled proteasome and MV151 in living GFP-b1i MelJuSo cells treated for 8 hr with 10 mM MV151. (D) GFP- b1i,
(E) Bodipy TMR fluorescence, and (F) a merged image are shown.
(G) In-gel visualization of proteasome labeling in living EL-4 cells: lane 1, a 1 hr incubation with MV151 (250 nM); lane 2, a 1 hr incubation with
MV151 (250 nM), followed by a 1 hr incubation with MG132 (5 mM); lane 3, a 1 hr incubation with MG132 (5 mM), followed by a 1 hr incubation
with MV151 (250 nM).
(H–J) CLSM pictures of Bodipy TMR fluorescence in MelJuSo Ub-R-GFP cells after formaldehyde fixation, gain 700. (H) Confocal picture after
a 1 hr incubation with MV151 (500 nM). (I) Confocal picture after a 1 hr incubation with MV151 (500 nM), followed by a 1 hr incubation with
MG132 (5 mM). (J) Confocal picture after a 1 hr incubation with MG132 (5 mM), followed by a 1 hr incubation with MV151 (500 nM).that stably express a GFP-tagged b1i proteasome sub-
unit, which is efficiently incorporated into the protea-
some particles [15]. The GFP-b1i fusion construct shows
ubiquitous distribution throughout the cytoplasm and
nucleus, with exception of nucleoli and the nuclear en-
velope (Figure 4D). The GFP-b1i cells were incubated
with 10 mM MV151 and the distribution of proteasomes
and inhibitor was compared. The intracellular perme-
ation of MV151 was monitored in time and is character-
ized by a fast permeation phase (several minutes), fol-
lowed by a slow distribution phase (several hours, data
not shown). During the permeation phase, the com-
pound showed significant association with the plasma
membrane, in discrete cytoplasmatic vesicular and
membranous fractions and at the nuclear envelope.
After 5 hr of distribution, MV151 is localized through-
out the cell, with the exception of the nucleoli, similar
to the GFP-b1i fusion (Figures 4D–4F). The fact thatMV151 is excluded from the nucleoli is in line with the
idea that the compound is associated with the protea-
some. In some cells, granular accumulation of MV151
was observed in the cytoplasm in close proximity to
the nucleus.
To attest whether the in-gel readout could be corre-
lated with the fluorescent microscopy data, MV151
was competed with the proteasome inhibitor MG132
(Figures 4G–4J). MelJuSo Ub-R-GFP cells incubated
with MV151 for 1 hr showed labeling of the active protea-
some subunits on gel (Figure 4G, lane 1) and, after fixa-
tion with formaldehyde, strong fluorescence in the cyto-
plasm and nucleus, with the exception of nucleoli
(Figure 4H). In Figure 4I, cells incubated with MV151
for 1 hr, followed by a 1 hr incubation with MG132,
showed labeling of the active proteasome subunits on
gel (Figure 4G, lane 2) and a similar cellular localization
to that shown in Figure 4H. When the cells where first
Chemistry & Biology
1222Figure 5. Functional Proteasome Inhibition in Mice
(A and B) Micrographs of (A) liver and (B) pancreas cryosections from C57Bl/6 mice that were treated with vehicle only or with MV151 (20 mmol/
kg body weight). Hoechst staining and Bodipy TMR fluorescence are shown. The scale bar represents 40 mm.
(C–G) Micrographs and in-gel fluorescence readout of (C and D) liver and (E and F) pancreas. (C and E) Cryosections from UbG76V-GFP mice
that were treated with vehicle only or with MV151 (20 mmol/kg body weight). Hoechst staining, Bodipy TMR fluorescence, UbG76V-GFP fluo-
rescence, and Bodipy TMR and UbG76V-GFP merged images are shown. The scale bar represents 40 mm (upper and middle panels) and 5
mm (lower panels). (D and F) SDS-PAGE analysis and in-gel fluorescence readout of homogenates (10 mg total protein) from liver and pancreas
tissues shown in (C) and (E), respectively, and (G) in spleen.incubated with MG132 for 1 hr, followed by a 1 hr incu-
bation with MV151, in-gel readout proved negative (Fig-
ure 4G, lane 3) and the fluorescence in the cells had dra-
matically decreased (Figure 4J). This competition study
proves that the vast majority of the fluorescence ob-
served in cells, after fixation, is due to proteasome
labeling.
Monitoring of Proteasome Inhibition in Mice
The results obtained in cell lines prompted us to investi-
gate whether MV151 could be used to label protea-
somes in mice. To test the bioavailability of MV151,
C57Bl/6 mice were given a single intraperitoneal injec-
tion with MV151 (20 mmol/kg body weight) and were sac-
rificed 24 hr postinjection.
Fluorescence microscopic analysis of mouse tissues
revealed the capacity of MV151 to penetrate tissues
in vivo. The highest Bodipy TMR fluorescence was de-tected in the liver (Figure 5A) and in the pancreas (Fig-
ure 5B). Interestingly, Bodipy TMR fluorescence was
higher in the peripheries of the tissues, indicating that
the probe might reach the liver most efficiently by diffu-
sion from the peritoneal cavity rather than being distrib-
uted by entering the bloodstream.
To examine the effect of administration of the protea-
some probe, we took advantage of a recently developed
transgenic mouse model for monitoring the ubiquitin-
proteasome system, which is based on the ubiquitous
expression of the UbG76V-GFP reporter [16]. We have
previously shown that administration of the proteasome
inhibitors epoxomicin and MG262 results in a substantial
accumulation of the UbG76V-GFP reporter in affected tis-
sues [16]. The accumulation was primarily found in the
liver and at higher concentrations in other tissues. In
the present experiment, the UbG76V-GFP reporter mice
were given a single intraperitoneal injection with
In Vivo Labeling of the Proteasome
1223Figure 6. MG262 Biodistribution Study in UbG76V-GFP Reporter Mice, followed by MV151 In-Gel Fluorescence Readout
(A and B) UbG76V-GFP reporter mice were treated with 0, 5, or 10 mmol/kg bodyweight MG262 by intraperitoneal injection and were sacrificed
after 24 hr. (A) Pancreas and (B) spleen were analyzed. Remaining activity of the b subunits in tissue homogenates was fluorescently labeled by
incubation with 0.1 mM MV151 for 1 hr at 37C. Cryosections of fixed (A) pancreas and (B) spleen were analyzed for accumulation of the re-
porter by confocal microscopy; green, GFP; blue, Hoechst nuclear stain.MV151 (20 mmol/kg body weight). A total of 24 hr postin-
jection, the mice were sacrificed and several tissues
were analyzed by fluorescence microscopy. Cells accu-
mulating UbG76V-GFP were detected in the liver
(Figure 5C) and the pancreas (Figure 5E), which also
contained the highest Bodipy TMR fluorescence of all
of the examined tissues (spleen, intestine, kidney, liver,
and pancreas). Importantly, all of the cells that accumu-
lated the UbG76V-GFP reporter contained very high Bod-
ipy TMR fluorescence. The proteasome probe was dis-
tributed both in the cytoplasm and nuclei of the cells
that accumulated the reporter. Similar to our observa-
tions from experiments in cell culture, the affected cells
in the mice contained granular accumulations of MV151
in the cytoplasm in close proximity to the nucleus. We
verified that accumulation of UbG76V-GFP in the liver
and pancreas coincided with proteasomal blockade by
MV151. SDS-PAGE followed by in-gel fluorescence
analysis of liver (Figure 5D) and pancreas (Figure 5F) ho-
mogenates of animals treated with MV151 revealed that
the proteasome catalytic subunits were labeled as ex-
pected, although higher background labeling compared
to in vitro studies was observed. (For Figures 5D and 5F,
respectively, the tissues from the images in Figures 5C
and 5E were used.) SDS-PAGE followed by in-gel fluo-
rescence analysis of spleen homogenates showed la-
beling of both constitutive and inducible proteasome
catalytic subunits (Figure 5G).
As the final set of experiments, we monitored the bio-
distribution of MG262 in UbG76V-GFP transgenic mice.
We selected the boronic acid MG262 for this purpose
because it is both commercially available in purified
form and most closely resembles the drug Bortezomib.Animals were injected subcutaneously with either 5
mmol/kg or 10 mmol/kg body weight of the boronic acid
MG262 and were sacrificed 24 hr postinjection. Spleen
and pancreas were lysed and treated with MV151.
SDS-PAGE analysis revealed significant reduction of la-
beled bands corresponding to the proteasome catalytic
subunits when compared with tissue lysates from un-
treated animals (Figure 6A, pancreas; Figure 6B, spleen).
Fluorescence microscope analysis of the same tissues
(Figures 6A and 6B) confirmed the concentration-de-
pendent inhibition of the proteasome in MG262-treated
UbG76V-GFP mice, as indicated by increased levels of
UbG76V-GFP reporter accumulation.
In summary, we described the synthesis of MV151
and characterized it as being a cell-permeable, broad-
spectrum proteasome inhibitor. MV151 enables broad-
spectrum proteasome profiling, both in cell lysates
and in living cells. The Bodipy TMR dye proved to be
very useful for in-gel readout of labeled active subunits
in that it provided a straightforward method for direct
and sensitive proteasome profiling and omitted the
need for western blotting, radioactivity, and gel drying.
MV151 could be readily detected upon administration
to mice and correlated with inhibition of the proteasome
in the affected tissues. Finally, MV151-mediated protea-
some labeling in combination with UbG76V-GFP trans-
genic mice is a useful strategy for monitoring the biodis-
tribution of proteasome inhibitors.
Significance
The proteasome is a key enzyme in the maintenance
of cellular homeostasis. Here, the synthesis and
Chemistry & Biology
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cell-permeable MV151 are presented. MV151 targets
the proteasome specifically and shows broad-spec-
trum activity by covalent and irreversible binding to
the catalytic N-terminal threonine residues of immu-
noinducible and constitutively active b subunits. The
bright fluorophore facilitates rapid and sensitive de-
tection of active proteasome subunits by in-gel detec-
tion and fluorescence microscopy in living cells. Po-
tentially, MV151 can find application in diverse fields
of proteasome research: in medical research, for pro-
filing the active proteasome fractions in a clinically rel-
evant sample; and in chemistry and biochemistry, fa-
cilitating rapid determination of potency and subunit
specificity of new proteasome inhibitors.
Experimental Procedures
Synthesis
General Methods and Materials
All reagents were commercial grade and were used as received un-
less indicated otherwise. Toluene (Tol.) (purum), ethyl acetate
(EtOAc) (puriss.), and light petroleum ether (PetEt) (puriss.) were ob-
tained from Riedel-de Hae¨n and were distilled prior to use. Dichloro-
ethane (DCE), dichloromethane (DCM), dimethyl formamide (DMF),
and dioxane (Biosolve) were stored on 4 A˚ molecular sieves. Tetra-
hydrofuran (THF) (Biosolve) was distilled from LiAlH4 prior to use.
Reactions were monitored by TLC analysis by using DC-fertigfolien
(Schleicher & Schuell, F1500, LS254) with detection by UV absorp-
tion (254 nm), spraying with 20% H2SO4 in ethanol, followed by char-
ring atw150C; by spraying with a solution of (NH4)6Mo7O24C4H2O
(25 g/L) and (NH4)4Ce(SO4)4C2H2O (10 g/L) in 10% sulfuric acid, fol-
lowed by charring atw150C; or by spraying with an aqueous solu-
tion of KMnO4 (7%) and KOH (2%). Column chromatography was
performed on Merck silicagel (0.040–0.063 nm). Electrospray ioniza-
tion mass spectra (MS [ESI]) were recorded on a PE/Sciex API 165
instrument interface, and HRMS (SIM mode) were recorded on
a TSQ Quantum (Thermo Finnigan) fitted with an accurate mass op-
tion, interpolating between PEG calibration peaks. 1H- and 13C-APT-
NMR spectra were recorded on a Jeol JNM-FX-200 (200/50.1) or
a Bruker AV-400 (400/100 MHz) equipped with a pulsed field gradi-
ent accessory. Chemical shifts are given in ppm (d) relative to tetra-
methylsilane as an internal standard. Coupling constants are given
in Hz. All presented 13C-APT spectra are proton decoupled. Optical
rotations were measured on a Propol automatic polarimeter (sodium
D line, l = 589 nm), and ATR-IR spectra were recorded on a Shi-
madzu FTIR-8300 fitted with a single bounce DurasamplIR diamond
crystal ATR element. UV spectra were recorded on a Perkin Elmer,
Lambda 800 UV/VIS spectrometer. Epoxomicin [17], dansyl-
Ahx3L3VS [7], NLVS [8], ZLVS [8], ada-Ahx3L3VS [6], and Boc-L3VS
[8] were synthesized as described in the literature. Supplemental
Data on the synthesis of Bodipy TMR succimidyl ester, 5, are
available.
TFA$L3VS, 2
Boc-L3VS (1) (0.47 g, 0.9 mmol) was dissolved in a mixture of TFA/
DCM (1/1) and was stirred for 30 min. The reaction mixture was con-
centrated in vacuo and afforded the TFA salt, 2, as a white solid was
used without further purification.
Fmoc-Ahx3-Wang, 3
Wang resin (1.8 g, 1.1 mmol/g, 2 mmol) was coevaporated with DCE
(23) and was condensed with Fmoc-Ahx-OH (2.1 g, 6 mmol, 3 equiv.)
under the influence of DIC (1.0 ml, 6.6 mmol, 3.3 equiv.) and DMAP
(12 mg, 0.1 mmol, 0.05 equiv.) for 2 hr. The resin was then filtered
and washed with DCM (33) and subjected to a second condensation
sequence. The loading of the resin was determined to be 0.8 mmol/g
(2.30 g, 1.84 mmol, 92%) by spectrophotometric analysis. The ob-
tained resin was submitted to two cycles of Fmoc solid-phase syn-
thesis with Fmoc-Ahx-OH, as follows: (i) deprotection with piperi-
dine/NMP (1/4, v/v, 15 min); (ii) wash with NMP (33); (iii) coupling
of Fmoc-Ahx-OH (1.63 g, 4.6 mmol, 2.5 equiv.) in the presence of
BOP (2.0 g, 4.6 mmol, 2.5 equiv.) and DiPEA (0.91 ml, 5.5 mmol,3 equiv.) in NMP and shaken for 2 hr; (iv) wash with NMP (33) and
DCM (33). Couplings were monitored for completion by the Kaiser
test [18].
Fmoc-Ahx3L3VS, 4
The tripeptide Fmoc-Ahx3-OH was released from resin 3 (0.45 mmol)
by treatment with TFA/DCM (1/1, v/v, 30 min, 33). The fractions were
collected and coevaporated with toluene (33). The crude Fmoc-
Ahx3-OH was dissolved in DCM/DMF (99/1, v/v) and condensed
with the crude TFA$L3VS (2) (0.9 mmol, 2 equiv.), under the influence
of BOP (0.49 g, 1.13 mmol, 2.5 equiv.) and DiPEA (0.45 ml, 2.7 mmol,
6 equiv.). The reaction mixture was stirred overnight, before being
concentrated in vacuo. The residue was dissolved in chloroform
and washed with 1 M HCl and sat. aq. NaHCO3. The organic layer
was dried over MgSO4 and concentrated. Silica column chromatog-
raphy (DCM / 4% MeOH in DCM) yielded the title compound, 4
(0.41 g, 0.44 mmol, 98%). 1H-NMR (500 MHz, CDCl3/MeOD): d 7.77
(d, J 7.5 Hz, 2H), 7.61 (d, J 7.5 Hz, 2H), 7.40 (t, J 7.5 Hz, 2H), 7.31 (t,
J 7.5 Hz, 2H), 6.82 (dd, J 15 Hz, J 5.0 Hz, 1H), 6.52 (d, J 15 Hz, 1H),
4.68 (m, 1H), 4.36 (m, 4H), 4.21 (t, J 6.8 Hz, 1H), 3.16 (m, 6H), 2.93
(s, 3H), 2.26–2.14 (m, 6H), 1.62–1.40 (m, 21H), 0.95–0.89 (m, 18H).
13C-NMR (125.8 MHz, CDCl3): d 174.15, 173.95, 173.87, 173.04,
172.96, 171.98, 171.90, 156.82, 156.78, 147.50, 143.66, 141.00,
128.84, 127.42, 124.74, 124.58, 119.67, 66.25, 51.82, 51.75, 47.62,
47.52, 46.95, 42.35, 42.15, 40.41, 40.28, 39.95, 38.88, 38.75, 35.92,
35.81, 35.49, 29.09, 28.59, 26.02, 25.94, 25.88, 25.06, 24.96, 24.84,
24.54, 24.50, 25.44, 22.52, 22.50, 22.48, 21.46, 21.36. ATR-IR (thin
film): 3294.2, 2935.5, 2862.2, 1685.7, 1627.8, 1539.1, 1450.4,
1365.5, 1307.6, 1257.5, 1130.2, 1080.1, 968.2, 833.2, 736.8, 667.3,
621.0 cm21. HRMS: calculated for C53H82N6O9SH 979.59368, found
979.59276.
Bodipy TMR-Ahx3L3VS, 6
DBU (30 ml, 0.2 mmol, 1 equiv.) was added to a solution of 4 (0.2 g, 0.2
mmol) in DMF. After 5 min of stirring, HOBt (0.12 g, 0.9 mmol, 4.5
equiv.) was added. To this mixture, Bodipy TMR-OSu (5) (0.1 g, 0.2
mmol, 1 equiv.) and DiPEA (0.2 ml, 1.2 mmol, 6 equiv.) were added,
and the mixture was stirred for 30 min before being concentrated in
vacuo. Purification by column chromatography (0.1% TEA in
DCM / 3% MeOH, 0.1% TEA in DCM) afforded Bodipy TMR-
Ahx3L3VS (6) (0.22 g, 197 mmol, 99%).
1H-NMR (500 MHz, CDCl3):
d 7.87 (d, J 8.5 Hz, 2H), 7.52 (s, 1H), 7.51 (s, 1H), 7.35 (d, J 8 Hz,
1H), 6.97 (m, 5H), 6.81 (dd, J 15 Hz, 5 Hz, 1H), 6.79 (s, 1H), 6.55 (d,
J 4 Hz, 1H), 6.51 (d, J 15 Hz), 4.67 (m, 1H), 4.33 (m, 2H), 3.86 (s,
3H), 3.17–3.10 (m, 6H), 2.96 (s, 3H), 2.74 (t, J 7.3, 2H), 2.53 (s, 3H),
2.30 (t, J 7.3, 2H), 2.21 (m, 5H), 2.14 (t, J 7.3, 2H), 2.08 (t, J 7.3, 2H),
1.66–1.17 (m, 27H), 0.95–0.89 (m, 18H). 13C-NMR (125.8 MHz,
CDCl3): d 174.40, 174.01, 173.94, 173.20, 172.53, 172.45, 172.06,
160.16, 159.44, 155.16, 147.61, 140.04, 134.77, 134.23, 130.46,
128.87, 128.30, 127.81, 125.29, 122.72, 118.10, 113.55, 55.12,
52.11, 52.04, 47.72, 45.98, 42.46, 42.26, 40.33, 40.00, 39.08, 38.94,
38.80, 35.93, 35.74, 35.62, 28.63, 28.49, 26.04, 25.99, 25.86, 25.03,
24.96, 24.88, 24.63, 24.60, 24.55, 22.66, 22.62, 22.58, 21.54, 21.48,
21.43, 20.09, 12.84, 9.27, 8.36. ATR-IR (thin film): 3290.3, 2927.7,
2866.0, 2160.1, 1975.0, 1631.7, 1604.7, 1539.1, 1461.9, 1434.9,
1369.4, 1292.2, 1230.5, 1203.5, 1172.6, 1130.2, 1056.9, 968.2, 833.2,
779.2, 659.6 cm21. HRMS: calculated for C59H91BF2N8O9SH
1137.67636, found 1137.67442; for C59H91BF2N8O9SNH4
1154.70291, found 1154.70149; for C59H91BF2N8O9SNa 1159.65831,
found 1159.65690. [a]D
23: 244 (c = 0.1, MeOH). lmax (MeOH):
544.43 nm, 3: 60400 liter mol21cm21.
Bodipy TMR-Ahx3L3ES, 7
A catalytic amount of 10% Pd on charcoal was added to a solution of
4 (49 mg, 50 mmol) in MeOH. Hydrogen gas was bubbled through the
solution for 2 hr, after which the catalyst was filtered of and the re-
action mixture was concentrated in vacuo. The residue was dis-
solved in DMF and treated with DBU (7.5 mL, 50 mmol, 1 equiv.) for
5 min before HOBt (30 mg, 0.23 mmol, 4.5 equiv.) was added. To
this mixture, Bodipy TMR-OSu (5) (25 mg, 50 mmol, 1 equiv.) and Di-
PEA (50 ml, 0.3 mol, 6 equiv.) were added, and the mixture was stirred
for 30 min before being concentrated in vacuo. Purification by col-
umn chromatography (0.1% TEA in DCM/ 3% MeOH, 0.1% TEA
in DCM) yielded Bodipy TMR-Ahx3L3ES (7) (50.3 mg, 44 mmol, 88
%). 1H-NMR (500 MHz, CDCl3/MeOD): d 7.78 (d, J 8.5 Hz, 2H), 7.41
(m, 1H), 7.18 (m, 1H), 7.08 (m, 3H), 6.80 (m, 3H), 6.47 (d, J 4 Hz,
1H), 4.18 (m, 2H), 3.92 (m, 1H), 3.78 (s, 3H), 3.07–2.99 (m, 6H), 2.87
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1225(s, 3H), 2.65 (t, J 7.5, 2H), 2.44 (s, 3H), 2.22 (t, J 7.5, 2H), 2.14 (m, 5H),
2.06 (t, J 7.3, 2H), 1.99 (t, J 7.5, 2H), 1.95 (m, 1H), 1.77 (m, 1H), 1.56–
1.11 (m, 27H), 0.88–0.78 (m, 18H). 13C-NMR (125.8 MHz, CDCl3):
d 174.57, 174.05, 173.14, 172.56, 172.39, 172.31, 160.10, 159.38,
155.08, 140.01, 134.72, 134.18, 130.39, 128.76, 127.96, 127.76,
125.23, 122.70, 117.34, 55.03, 52.26, 52.15, 51.28, 46.03, 45.95,
43.64, 40.17, 40.11, 39.90, 38.91, 38.78, 35.83, 35.77, 35.68, 35.45,
28.56, 28.41, 27.87, 26.02, 25.96, 25.84, 25.02, 24.96, 24.83, 24.63,
24.57, 24.53, 22.72, 22.52, 21.51, 21.37, 21.23. ATR-IR (thin film):
3274.9, 2929.7, 2869.9, 1635.5, 1604.7, 1527.5, 1461.9, 1436.9,
1386.7, 1292.2, 1234.4, 1201.6, 1174.7, 1136.9, 1120.6, 1058.8,
1029.9, 972.1, 839.0, 786.9, 717.5, 663.5 cm21. HRMS: calculated
for C59H93BF2N8O9SH 1139.69201, found 1139.69203.
Proteasomal Activity Measurement with Fluorogenic
Substrates
Protein lysates from EL-4 (1 mg/ml) were incubated with various
concentrations of MV151 (6) for 1 hr at 37C. For measurement of
proteasomal activities, 10 mg labeled lysate was added to 100 ml sub-
strate buffer, containing 20 mM HEPES (pH 8.2), 0.5 mM EDTA, 1%
DMSO, 1 mM ATP, and 10 mM Z-Ala-Ala-Arg-AMC (tryptic-like), 60
mM Suc-Leu-Leu-Val-Tyr-AMC (chymotryptic-like), or 60 mM Z-
Leu-Leu-Glu-bNA (caspase-like). Fluorescence was measured every
minute for 25 min at 37C by using a Fluostar Optima 96-well plate
reader (BMG Labtechnologies) (lex/lem = 355/450 nm for AMC and
320/405 nm for bNA), and the maximum increase in fluorescence
per minute was used to calculate specific activities of each sample.
Nonspecific hydrolysis was assessed by preincubation with 1 mM
epoxomicin for 1 hr at 37C and was subtracted from each
measurement.
In-Gel Detection of Labeled Proteasome Subunits
Whole-cell lysates were made in lysis buffer containing 50 mM Tris
(pH 7.5), 1 mM DTT, 5 mM MgCl2, 250 mM sucrose, 2 mM ATP. Pro-
tein concentration was determined by the colorimetric Bradford
method. For the labeling reactions, 10 mg total protein lysates was
incubated for 1 hr at 37C with increasing concentrations of
MV151 in a total reaction volume of 10 ml. Where indicated, 50 ng pu-
rified 20S proteasome (BioMol) was used. For competition studies,
cell lysates (10 mg) were exposed to the known inhibitors for 1 hr
prior to incubation with MV151 (0.1 mM) for 1 hr at 37C. For assess-
ment of background labeling, heat-inactivated lysates (10 mg, boiled
for 3 min with 1% SDS) were treated with MV151. Reaction mixtures
were boiled with Laemmli’s buffer containing b-mercapto-ethanol
for 3 min and were resolved on 12.5% SDS-PAGE. In-gel visualiza-
tion was performed in the wet gel slabs directly by using the Cy3/
Tamra settings (lex 532, lem 560) on the Typhoon Variable Mode Im-
ager (Amersham Biosciences). Labeling profiles in living cells were
determined by incubatingw13 106 cells with 1–10 mM MV151 in cul-
ture medium at 37C for 8 hr. Cells were lysed, and in-gel detection
was carried out as described above.
Cell Culture
The human cervical epithelial carcinoma cell line HeLa, the human
melanoma cell line MelJuSo, and the murine lymphoid cell line EL-
4 were cultured in RPMI medium (Sigma-Aldrich) supplemented
with 10% fetal calf serum (Sigma-Aldrich), 10 U/ml penicillin, and
10 mg/ml streptomycin (Sigma-Aldrich).
Microscopy
Some 0.53 106 cells were seeded on 35 mm petri dishes with 14 mm
microwell nr 1.5 coverslips and on glass-bottomed microwell dishes
(MatTek Corp., Ashland, MA) and were allowed to attach overnight.
Cells were visualized with a 603 oil immersion lens (Nikon) on a Ni-
kon Eclipse TE 2000U microscope equipped with a Radiance 2100
MP integrated laser and detection system (BioRad) and a Tsunami
Multiphoton laser module (Spectra Physics). LaserSharp 2K (Bio-
Rad) software was used for microscope control and data acquisi-
tion, and Image Pro 3DS 5.1 (Media Cybernetics, Inc.) software
was used for image processing. GFP was excited at lex = 488 nm
and was detected at 500–530 nm. MV151 and MV152 were excited
at lex = 543 nm and were detected at 560–620 nm. CLSM images
were adjusted for brightness and contrast by using Photoshop
software.Mouse Experiments
All animal experiments were approved by the Ethical Committee in
Stockholm (ethical permission numbers N-46/04 and N18/05).
Mice were housed according to Swedish animal care protocols
with a 12 hr day/light cycle, and they were fed standard laboratory
chow and tap water ad libitum. Adult C57Bl/6 and UbG76V-GFP/1
mice [16], matched for sex and age, were given a single intraperito-
neal injection of vehicle (60% DMSO, 40% PBS), MV151 (20 mmol/kg
body weight), or MG262 (Affiniti) (5 or 10 mmol/kg body weight) in
a total volume of 200 ml. Based on prior experience in our lab, the bo-
ronic acid inhibitors proved to be more potent and showed better
tissue penetration in vivo compared to the vinyl sulfone inhibitors.
Therefore, the 20 mmol/kg bodyweight dose was chosen for
MV151, which showed no apparent toxicity in mice. Mice were eu-
thanized 24 hr postinjection by anesthetization with inhaled isoflur-
ane (4.4% in oxygen), followed by transcardial perfusion with 50
ml PBS for removal of contaminating blood. Tissues collected for
immunocytochemical analysis were processed as described previ-
ously [16]. Briefly, 12 mm cryosections were fixed for 15 min in 4%
paraformaldehyde/PBS and washed in PBS; where mentioned,
Hoechst nuclear stain (2 mg/ml in H2O) was applied for 15 min in
the dark, followed by washing in PBS. Sections were mounted in
a matrix containing 2.5% DABCO (Aldrich). Confocal microscopy
was performed on a Zeiss LSM 510 META system. Tissues isolated
for in-gel analysis were lysed with a Heidolph tissue homogenizer in
300 ml lysis buffer and were further treated as described above.
Supplemental Data
Supplemental Data include information on the synthesis and analyt-
ical data of the Bipody TMR-succimidyl ester, 5, and are available at
http://www.chembiol.com/cgi/content/full/13/11/1217/DC1/.
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